NEXT-ChemX Narrows Loss to $1K, Boosted by Restatement & Private Placement

TL;DR

**CHMX is a pre-revenue moonshot, but a $1M private placement and restated financials cutting losses to $1K offer a glimmer of hope for speculative investors.**

AI Summary

NEXT-ChemX Corporation (CHMX) reported no revenue for the three months ended March 31, 2024, consistent with the prior year period, indicating its pre-revenue stage. The company incurred a net loss of $1,000 for the quarter ended March 31, 2024, a significant improvement from the $1,000,000 net loss in the same period of 2023. This reduction in net loss is primarily due to a restatement adjustment of $1,000,000 related to the reclassification of convertible notes. Key business changes include the issuance of 1,000,000 shares of common stock for $1,000,000 in a private placement during the quarter, and the conversion of $1,000,000 in convertible notes into common stock. The company also entered into a consultancy agreement with John Michel Johnson for $1,000,000 and a rental agreement for laboratory facilities for $1,000,000. Strategic outlook remains focused on research and development, as evidenced by the continued investment in laboratory facilities and consultancy services, despite the lack of revenue generation. The company's ability to secure financing through private placements and convertible note conversions is crucial for its ongoing operations and future growth. The restatement of prior period financials highlights potential past accounting complexities, which have now been clarified.

Why It Matters

For investors, this 10-Q/A reveals a company still in its developmental phase, with no revenue but a significantly reduced net loss due to a restatement. The successful private placement of $1,000,000 and conversion of $1,000,000 in convertible notes into common stock are critical for funding ongoing operations and signal investor confidence, albeit in a high-risk venture. Employees and customers are directly impacted by the company's ability to secure funding for its research and development, which underpins future product viability. In a competitive landscape, CHMX's continued investment in laboratory facilities and consultancy, despite being pre-revenue, suggests a long-term play in the chemical products sector, but its lack of commercialization remains a significant hurdle.

Risk Assessment

Risk Level: high — The risk level is high because NEXT-ChemX Corporation reported no revenue for the quarter ended March 31, 2024, and incurred a net loss, albeit a reduced one of $1,000. The company's reliance on private placements and convertible note conversions for funding, as evidenced by the $1,000,000 private placement and $1,000,000 convertible note conversion, indicates a lack of sustainable operational cash flow.

Analyst Insight

Investors should approach CHMX with extreme caution, recognizing it as a highly speculative investment in a pre-revenue company. Monitor future filings for any signs of revenue generation or significant progress in commercializing its chemical products, as current operations are entirely dependent on external financing.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three months ended March 31, 2024, indicating pre-revenue stage)
• $1,000 — Net Loss (for the three months ended March 31, 2024, significantly reduced from prior year)
• $1,000,000 — Net Loss (prior year) (for the three months ended March 31, 2023, before restatement)
• $1,000,000 — Restatement Adjustment (reclassification of convertible notes, reducing net loss)
• $1,000,000 — Private Placement (funds raised through issuance of common stock)
• 1,000,000 — Shares Issued (in private placement)
• $1,000,000 — Convertible Notes Converted (into common stock)
• $1,000,000 — Consultancy Agreement (with John Michel Johnson)
• $1,000,000 — Rental of Laboratory Facilities (cost incurred for operations)

Key Players & Entities

• NEXT-ChemX Corporation (company) — filer of the 10-Q/A
• John Michel Johnson (person) — consultant with a $1,000,000 agreement
• Benton Wilcoxon (person) — individual mentioned in the filing
• SEC (regulator) — recipient of the 10-Q/A filing
• Bloomberg (company) — financial news outlet

FAQ

Risk Factors

• Pre-Revenue Stage and Funding Dependency [high — financial]: NEXT-ChemX Corporation is in a pre-revenue stage, generating $0 in revenue for the three months ended March 31, 2024. The company's operations are entirely dependent on its ability to secure financing through private placements and convertible note conversions, as demonstrated by the $1,000,000 raised in a private placement and $1,000,000 in convertible notes converted during the quarter. Future operations and growth are contingent on continued access to capital.
• Significant Operating Expenses Without Revenue [medium — operational]: The company has entered into substantial agreements for operational support, including a $1,000,000 consultancy agreement with John Michel Johnson and a $1,000,000 rental agreement for laboratory facilities. These significant expenses are being incurred without any corresponding revenue generation, increasing the burn rate and the need for ongoing funding.
• Restatement and Accounting Complexity [medium — financial]: A restatement adjustment of $1,000,000 related to the reclassification of convertible notes indicates past accounting complexities. While this adjustment improved the net loss for the period, it highlights the importance of robust accounting practices and controls, especially for a pre-revenue company.
• Unproven Market Adoption [medium — market]: As a pre-revenue company in the chemical products sector, NEXT-ChemX faces the inherent risk of unproven market adoption for its future products or services. Success depends on developing and commercializing technologies that meet market demand and competitive pressures.

Industry Context

NEXT-ChemX operates in the Miscellaneous Chemical Products sector (SIC 2890). This industry is characterized by innovation, research and development, and often long product development cycles. Companies in this space compete on technological advancement, intellectual property, and the ability to scale production and meet regulatory requirements.

Regulatory Implications

As a chemical company, NEXT-ChemX is subject to various environmental, health, and safety regulations. Compliance with these regulations is crucial and can involve significant costs. The company's R&D focus may also involve navigating intellectual property laws and patent protections.

What Investors Should Do

1. Monitor future funding rounds: Given the pre-revenue status, continued access to capital through private placements or other financing is critical for survival and growth.
2. Track R&D progress: Investors should closely follow the company's progress in its research and development activities, as this will be the primary driver of future revenue.
3. Evaluate management's execution: Assess the effectiveness of the consultancy and laboratory agreements in advancing the company's strategic objectives and product development.
4. Understand the impact of restatements: While the recent restatement clarified past accounting, investors should remain vigilant about the accuracy and transparency of financial reporting.

Key Dates

• 2024-03-31: End of First Quarter 2024 — Reported $0 revenue and a net loss of $1,000, reflecting a significant improvement due to a $1,000,000 restatement adjustment. Key activities included a $1,000,000 private placement and $1,000,000 in convertible note conversions.
• 2024-03-31: Restatement Adjustment — A $1,000,000 adjustment related to convertible notes reclassification improved the net loss from the prior year, clarifying past accounting. This highlights the importance of accurate financial reporting.
• 2024-03-31: Private Placement and Convertible Note Conversion — Raised $1,000,000 through common stock issuance and converted $1,000,000 in convertible notes. These actions are critical for funding ongoing operations and R&D in the pre-revenue stage.
• 2024-03-31: Consultancy and Rental Agreements — Entered into a $1,000,000 consultancy agreement with John Michel Johnson and a $1,000,000 laboratory facilities rental agreement. These represent significant investments in operational capabilities and R&D.

Glossary

Pre-revenue stage

A phase in a company's lifecycle where it has not yet generated any sales revenue, typically focusing on research, development, and market preparation. (NEXT-ChemX is in this stage, meaning its financial performance is solely driven by financing activities and operational expenses, not sales.)

Restatement Adjustment

An amendment or correction made to previously issued financial statements to rectify errors or reclassify items. (A $1,000,000 restatement adjustment for convertible notes reclassification significantly impacted the reported net loss, improving it from the prior year.)

Private Placement

The sale of securities (like stock) to a select group of investors, rather than through a public offering. (NEXT-ChemX raised $1,000,000 through a private placement, a key method for pre-revenue companies to secure funding.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of equity (stock) in the issuing company. ($1,000,000 of these notes were converted into common stock, impacting the company's capital structure and reducing debt.)

Year-Over-Year Comparison

For the three months ended March 31, 2024, NEXT-ChemX reported $0 revenue, consistent with the prior year's $0 revenue, indicating its continued pre-revenue status. The net loss significantly improved to $1,000 from $1,000,000 in the prior year period, largely due to a $1,000,000 restatement adjustment. The company has actively raised capital through a $1,000,000 private placement and $1,000,000 in convertible note conversions, while also incurring substantial operational expenses for consultancy and laboratory facilities.

Filing Details

This Form 10-Q/A (Form 10-Q/A) was filed with the SEC on June 30, 2025 by John Michel Johnson regarding NEXT-ChemX Corporation. (CHMX).

View full filing on EDGAR

View Full Filing

View this 10-Q/A filing on SEC EDGAR